On a related note, the cost of skilled nursing care under Medicare Part A is also higher this year. For days 21 through 100 at a skilled nursing facility, your daily coinsurance c
U.S. Senator Jacky Rosen announced that 15 additional medications have been selected for Medicare drug pricing negotiations, aiming to reduce costs for seniors
WASHINGTON — Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, further complicating big decisions the Trump administration will have to make about how to cover the medications.
Medicare Payment Advisory Commission recommends tying physician payment update to care cost growth; AMA calls for Congress to act on analysis.
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.
Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.
The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.
The 15 drugs selected for negotiation are prescribed to 5.3 million Medicare beneficiaries to treat conditions ranging from cancer and type 2 diabetes to asthma.
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.
Under legislation passed in 2022 called the Inflation Reduction Act, Medicare was allowed for the first time to negotiate prices with drug companies on a limited number of medications.